Soluble Epoxide Hydrolase Deficiency or Inhibition Attenuates MPTP-Induced Parkinsonism

Molecular Neurobiology

Volumn 52, Issue 1, 2015, Pages 187-195

  Qin, Xiaocui ^a   Wu, Qiaoqi ^a   Lin, Lifang ^a   Sun, Aimin ^a   Liu, Shuhu ^a   Li, Xiaowen ^a   Cao, Xiong ^a   Gao, Tianming ^a   Luo, Pengcheng ^b   Zhu, Xinhong ^a   Wang, Xuemin ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b Hubei Polytechnic University   (China)

Author keywords

EET; MPTP; Parkinson s disease; Soluble epoxide hydrolase

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 12 (3 ADAMANTAN 1 YL UREIDO)DODECANOIC ACID; 14,15 EPOXY 5,8,11 ICOSATRIENOIC ACID; DOPAMINE; EPOXIDE HYDROLASE; HYDROLASE INHIBITOR; PARAQUAT; PROTEIN KINASE B; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG; 12-(3-ADAMANTAN-1-YLUREIDO)DODECANOIC ACID; 14,15-EPOXY-5,8,11-EICOSATRIENOIC ACID; ADAMANTANE; DIHOMO GAMMA LINOLENIC ACID; LAURIC ACID DERIVATIVE; NEUROPROTECTIVE AGENT;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CELL; CELL LOSS; CELL PROTECTION; CONTROLLED STUDY; DISEASE MODEL; DOPAMINERGIC NERVE CELL; ENZYME DEFICIENCY; ENZYME INACTIVATION; ENZYME INHIBITION; KNOCKOUT MOUSE; MALE; MOUSE; NERVE CELL CULTURE; NEUROPROTECTION; NONHUMAN; PARKINSONISM; PROTEIN EXPRESSION; ROTAROD TEST; TASK PERFORMANCE; WILD TYPE; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CELL CULTURE; CELL SURVIVAL; CHEMICALLY INDUCED; DEFICIENCY; DRUG EFFECTS; ENZYMOLOGY; METABOLISM; PARKINSONIAN DISORDERS; PATHOLOGY; SOLUBILITY; SUBSTANTIA NIGRA; UPREGULATION;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; 8,11,14-EICOSATRIENOIC ACID; ADAMANTANE; ANIMALS; BEHAVIOR, ANIMAL; CELL SURVIVAL; CELLS, CULTURED; DOPAMINERGIC NEURONS; EPOXIDE HYDROLASES; LAURIC ACIDS; MALE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEUROPROTECTIVE AGENTS; PARAQUAT; PARKINSONIAN DISORDERS; ROTAROD PERFORMANCE TEST; SOLUBILITY; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE; UP-REGULATION;

EID: 84937967016     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-014-8833-3     Document Type: Article

References (24)

1. Morisseau C, Hammock BD (2013) Impact of soluble epoxide hydrolase and epoxyeicosanoids on human health. Annu Rev Pharmacol Toxicol 53:37–58
2. Sura P, Sura R, Enayetallah AE, Grant DF (2008) Distribution and expression of soluble epoxide hydrolase in human brain. J Histochem Cytochem 56(6):551–559
3. Luo B, Norris C, Bolstad ES, Knecht DA, Grant DF (2008) Protein quaternary structure and expression levels contribute to peroxisomal-targeting-sequence-1-mediated peroxisomal import of human soluble epoxide hydrolase. J Mol Biol 380(1):31–41
4. Revermann M (2010) Pharmacological inhibition of the soluble epoxide hydrolase—from mouse to man. Curr Opin Pharmacol 10(2):173–178
5. Sudhahar V, Shaw S, Imig JD (2010) Epoxyeicosatrienoic acid analogs and vascular function. Curr Med Chem 17(12):1181–1190
6. Luria A, Bettaieb A, Xi Y, Shieh GJ, Liu HC, Inoue H, Tsai HJ, Imig JD, Haj FG, Hammock BD (2011) Soluble epoxide hydrolase deficiency alters pancreatic islet size and improves glucose homeostasis in a model of insulin resistance. Proc Natl Acad Sci U S A 108(22):9038–9043
7. Roman RJ (2002) P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev 82(1):131–185
8. Imig JD (2005) Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases. Am J Physiol Ren Physiol 289(3):F496–503
9. Imig JD (2012) Epoxides and soluble epoxide hydrolase in cardiovascular physiology. Physiol Rev 92(1):101–130
10. Eriksen JL, Wszolek Z, Petrucelli L (2005) Molecular pathogenesis of Parkinson disease. Arch Neurol 62(3):353–357
11. Gupta A, Dawson VL, Dawson TM (2008) What causes cell death in Parkinson’s disease? Ann Neurol 64(Suppl 2):S3–15
12. Sinal CJ, Miyata M, Tohkin M, Nagata K, Bend JR, Gonzalez FJ (2000) Targeted disruption of soluble epoxide hydrolase reveals a role in blood pressure regulation. J Biol Chem 275(51):40504–40510
13. Tomac A, Lindqvist E, Lin LF, Ogren SO, Young D, Hoffer BJ, Olson L (1995) Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature 373(6512):335–339
14. McCormack AL, Thiruchelvam M, Manning-Bog AB, Thiffault C, Langston JW, Cory-Slechta DA, Di Monte DA (2002) Environmental risk factors and Parkinson’s disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat. Neurobiol Dis 10(2):119–127
15. Xia Z, Dudek H, Miranti CK, Greenberg ME (1996) Calcium influx via the NMDA receptor induces immediate early gene transcription by a MAP kinase/ERK-dependent mechanism. J Neurosci 16(17):5425–5436
16. Chen JK, Capdevila J, Harris RC (2001) Cytochrome p450 epoxygenase metabolism of arachidonic acid inhibits apoptosis. Mol Cell Biol 21(18):6322–6331
17. Liu M, Hunter R, Nguyen XV, Kim HC, Bing G (2008) Microsomal epoxide hydrolase deletion enhances tyrosine hydroxylase phosphorylation in mice after MPTP treatment. J Neurosci Res 86(12):2792–2801
18. Bellien J, Joannides R (2013) Epoxyeicosatrienoic acid pathway in human health and diseases. J Cardiovasc Pharmacol 61(3):188–196
19. Zhang W, Koerner IP, Noppens R, Grafe M, Tsai HJ, Morisseau C, Luria A, Hammock BD, Falck JR, Alkayed NJ (2007) Soluble epoxide hydrolase: a novel therapeutic target in stroke. J Cereb Blood Flow Metab 27(12):1931–1940
20. Koerner IP, Jacks R, DeBarber AE, Koop D, Mao P, Grant DF, Alkayed NJ (2007) Polymorphisms in the human soluble epoxide hydrolase gene EPHX2 linked to neuronal survival after ischemic injury. J Neurosci 27(17):4642–4649
21. Zhang W, Otsuka T, Sugo N, Ardeshiri A, Alhadid YK, Iliff JJ, DeBarber AE, Koop DR, Alkayed NJ (2008) Soluble epoxide hydrolase gene deletion is protective against experimental cerebral ischemia. Stroke 39(7):2073–2078
22. Dunnett SB, Bjorklund A (1999) Prospects for new restorative and neuroprotective treatments in Parkinson’s disease. Nature 399(6738 Suppl):A32–39
23. Seubert JM, Sinal CJ, Graves J, DeGraff LM, Bradbury JA, Lee CR, Goralski K, Carey MA, Luria A, Newman JW, Hammock BD, Falck JR, Roberts H, Rockman HA, Murphy E, Zeldin DC (2006) Role of soluble epoxide hydrolase in postischemic recovery of heart contractile function. Circ Res 99(4):442–450
24. Imig JD, Zhao X, Capdevila JH, Morisseau C, Hammock BD (2002) Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. Hypertension 39(2 Pt 2):690–694